Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
Identifieur interne : 000E79 ( Main/Exploration ); précédent : 000E78; suivant : 000E80Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
Auteurs : Evan M. Bloch [États-Unis] ; Ruchika Goel [États-Unis] ; Silvano Wendel [Brésil] ; Thierry Burnouf [Taïwan] ; Arwa Z. Al-Riyami ; Ai Leen Ang [Singapour] ; Vincenzo Deangelis [Italie] ; Larry J. Dumont [États-Unis] ; Kevin Land [États-Unis] ; Cheuk-Kwong Lee [République populaire de Chine] ; Adaeze Oreh [Nigeria] ; Gopal Patidar [Inde] ; Steven L. Spitalnik [États-Unis] ; Marion Vermeulen [Afrique du Sud] ; Salwa Hindawi [Arabie saoudite] ; Karin Van Den Berg [Afrique du Sud] ; Pierre Tiberghien [France] ; Hans Vrielink [Pays-Bas] ; Pampee Young [États-Unis] ; Dana Devine [Canada] ; Cynthia So-Osman [Pays-Bas]Source :
- Vox sanguinis [ 1423-0410 ] ; 2020.
Abstract
BACKGROUND AND OBJECTIVES
COVID-19 convalescent plasma (CCP) has been used, predominantly in high-income countries (HICs) to treat COVID-19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low- and middle-income countries (LMICs) for which data are lacking.
MATERIALS AND METHODS
A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and haematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self-identified expertise and interest. Here, the donor and product-related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices.
RESULTS
The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre-donation qualification and operational considerations could impede wide adoption.
CONCLUSION
There has been wide-scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.
DOI: 10.1111/vox.12970
PubMed: 32533868
PubMed Central: PMC7323328
Affiliations:
- Afrique du Sud, Arabie saoudite, Brésil, Canada, France, Inde, Italie, Nigeria, Pays-Bas, République populaire de Chine, Singapour, Taïwan, États-Unis
- Arizona, Colorado, Illinois, Maryland, New Hampshire, Texas, État de New York, État de São Paulo, Île-de-France
- New York, Paris, São Paulo
- Université Columbia
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.</title><author><name sortKey="Bloch, Evan M" sort="Bloch, Evan M" uniqKey="Bloch E" first="Evan M" last="Bloch">Evan M. Bloch</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Goel, Ruchika" sort="Goel, Ruchika" uniqKey="Goel R" first="Ruchika" last="Goel">Ruchika Goel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Wendel, Silvano" sort="Wendel, Silvano" uniqKey="Wendel S" first="Silvano" last="Wendel">Silvano Wendel</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Sirio Libanês, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Hospital Sirio Libanês, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Al Riyami, Arwa Z" sort="Al Riyami, Arwa Z" uniqKey="Al Riyami A" first="Arwa Z" last="Al-Riyami">Arwa Z. Al-Riyami</name><affiliation><nlm:affiliation>Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.</nlm:affiliation><wicri:noCountry code="subField">Sultanate of Oman</wicri:noCountry></affiliation></author><author><name sortKey="Ang, Ai Leen" sort="Ang, Ai Leen" uniqKey="Ang A" first="Ai Leen" last="Ang">Ai Leen Ang</name><affiliation wicri:level="1"><nlm:affiliation>Blood Services Group, Health Sciences Authority, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Blood Services Group, Health Sciences Authority, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Deangelis, Vincenzo" sort="Deangelis, Vincenzo" uniqKey="Deangelis V" first="Vincenzo" last="Deangelis">Vincenzo Deangelis</name><affiliation wicri:level="1"><nlm:affiliation>Transfusion Medicine Dept, Udine University Hospital, Udine, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Transfusion Medicine Dept, Udine University Hospital, Udine</wicri:regionArea><wicri:noRegion>Udine</wicri:noRegion></affiliation></author><author><name sortKey="Dumont, Larry J" sort="Dumont, Larry J" uniqKey="Dumont L" first="Larry J" last="Dumont">Larry J. Dumont</name><affiliation wicri:level="2"><nlm:affiliation>Vitalant Research Institute, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vitalant Research Institute, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>University of Colorado School of Medicine, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado School of Medicine, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Geisel School of Medicine at Dartmouth, Lebanon, NH</wicri:regionArea><placeName><region type="state">New Hampshire</region></placeName></affiliation></author><author><name sortKey="Land, Kevin" sort="Land, Kevin" uniqKey="Land K" first="Kevin" last="Land">Kevin Land</name><affiliation wicri:level="2"><nlm:affiliation>Vice President Clinical Services, Vitalant, Scottsdale, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vice President Clinical Services, Vitalant, Scottsdale, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lee, Cheuk Kwong" sort="Lee, Cheuk Kwong" uniqKey="Lee C" first="Cheuk-Kwong" last="Lee">Cheuk-Kwong Lee</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China</wicri:regionArea><wicri:noRegion>China</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>King's Park Rise, Kowloon, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>King's Park Rise, Kowloon</wicri:regionArea><wicri:noRegion>Kowloon</wicri:noRegion></affiliation></author><author><name sortKey="Oreh, Adaeze" sort="Oreh, Adaeze" uniqKey="Oreh A" first="Adaeze" last="Oreh">Adaeze Oreh</name><affiliation wicri:level="1"><nlm:affiliation>National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja</wicri:regionArea><wicri:noRegion>Abuja</wicri:noRegion></affiliation></author><author><name sortKey="Patidar, Gopal" sort="Patidar, Gopal" uniqKey="Patidar G" first="Gopal" last="Patidar">Gopal Patidar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Spitalnik, Steven L" sort="Spitalnik, Steven L" uniqKey="Spitalnik S" first="Steven L" last="Spitalnik">Steven L. Spitalnik</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology & Cell Biology, Columbia University, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology & Cell Biology, Columbia University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Vermeulen, Marion" sort="Vermeulen, Marion" uniqKey="Vermeulen M" first="Marion" last="Vermeulen">Marion Vermeulen</name><affiliation wicri:level="1"><nlm:affiliation>The South African National Blood Service, Johannesbur, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The South African National Blood Service, Johannesbur</wicri:regionArea><wicri:noRegion>Johannesbur</wicri:noRegion></affiliation></author><author><name sortKey="Hindawi, Salwa" sort="Hindawi, Salwa" uniqKey="Hindawi S" first="Salwa" last="Hindawi">Salwa Hindawi</name><affiliation wicri:level="1"><nlm:affiliation>Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Berg, Karin" sort="Van Den Berg, Karin" uniqKey="Van Den Berg K" first="Karin" last="Van Den Berg">Karin Van Den Berg</name><affiliation wicri:level="1"><nlm:affiliation>The South African National Blood Service, Johannesbur, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The South African National Blood Service, Johannesbur</wicri:regionArea><wicri:noRegion>Johannesbur</wicri:noRegion></affiliation></author><author><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name><affiliation wicri:level="3"><nlm:affiliation>Etablissement Français du Sang, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vrielink, Hans" sort="Vrielink, Hans" uniqKey="Vrielink H" first="Hans" last="Vrielink">Hans Vrielink</name><affiliation wicri:level="1"><nlm:affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author><author><name sortKey="Young, Pampee" sort="Young, Pampee" uniqKey="Young P" first="Pampee" last="Young">Pampee Young</name><affiliation wicri:level="1"><nlm:affiliation>American Red Cross, Washington, D.C, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>American Red Cross, Washington, D.C</wicri:regionArea><wicri:noRegion>D.C</wicri:noRegion></affiliation></author><author><name sortKey="Devine, Dana" sort="Devine, Dana" uniqKey="Devine D" first="Dana" last="Devine">Dana Devine</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Blood Services, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Blood Services, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="So Osman, Cynthia" sort="So Osman, Cynthia" uniqKey="So Osman C" first="Cynthia" last="So-Osman">Cynthia So-Osman</name><affiliation wicri:level="1"><nlm:affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Erasmus Medical Center, Rotterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Haematology, Erasmus Medical Center, Rotterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32533868</idno><idno type="pmid">32533868</idno><idno type="doi">10.1111/vox.12970</idno><idno type="pmc">PMC7323328</idno><idno type="wicri:Area/Main/Corpus">000E06</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E06</idno><idno type="wicri:Area/Main/Curation">000E06</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E06</idno><idno type="wicri:Area/Main/Exploration">000E06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.</title><author><name sortKey="Bloch, Evan M" sort="Bloch, Evan M" uniqKey="Bloch E" first="Evan M" last="Bloch">Evan M. Bloch</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Goel, Ruchika" sort="Goel, Ruchika" uniqKey="Goel R" first="Ruchika" last="Goel">Ruchika Goel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Wendel, Silvano" sort="Wendel, Silvano" uniqKey="Wendel S" first="Silvano" last="Wendel">Silvano Wendel</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Sirio Libanês, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Hospital Sirio Libanês, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Al Riyami, Arwa Z" sort="Al Riyami, Arwa Z" uniqKey="Al Riyami A" first="Arwa Z" last="Al-Riyami">Arwa Z. Al-Riyami</name><affiliation><nlm:affiliation>Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.</nlm:affiliation><wicri:noCountry code="subField">Sultanate of Oman</wicri:noCountry></affiliation></author><author><name sortKey="Ang, Ai Leen" sort="Ang, Ai Leen" uniqKey="Ang A" first="Ai Leen" last="Ang">Ai Leen Ang</name><affiliation wicri:level="1"><nlm:affiliation>Blood Services Group, Health Sciences Authority, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Blood Services Group, Health Sciences Authority, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Deangelis, Vincenzo" sort="Deangelis, Vincenzo" uniqKey="Deangelis V" first="Vincenzo" last="Deangelis">Vincenzo Deangelis</name><affiliation wicri:level="1"><nlm:affiliation>Transfusion Medicine Dept, Udine University Hospital, Udine, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Transfusion Medicine Dept, Udine University Hospital, Udine</wicri:regionArea><wicri:noRegion>Udine</wicri:noRegion></affiliation></author><author><name sortKey="Dumont, Larry J" sort="Dumont, Larry J" uniqKey="Dumont L" first="Larry J" last="Dumont">Larry J. Dumont</name><affiliation wicri:level="2"><nlm:affiliation>Vitalant Research Institute, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vitalant Research Institute, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>University of Colorado School of Medicine, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado School of Medicine, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Geisel School of Medicine at Dartmouth, Lebanon, NH</wicri:regionArea><placeName><region type="state">New Hampshire</region></placeName></affiliation></author><author><name sortKey="Land, Kevin" sort="Land, Kevin" uniqKey="Land K" first="Kevin" last="Land">Kevin Land</name><affiliation wicri:level="2"><nlm:affiliation>Vice President Clinical Services, Vitalant, Scottsdale, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vice President Clinical Services, Vitalant, Scottsdale, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lee, Cheuk Kwong" sort="Lee, Cheuk Kwong" uniqKey="Lee C" first="Cheuk-Kwong" last="Lee">Cheuk-Kwong Lee</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China</wicri:regionArea><wicri:noRegion>China</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>King's Park Rise, Kowloon, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>King's Park Rise, Kowloon</wicri:regionArea><wicri:noRegion>Kowloon</wicri:noRegion></affiliation></author><author><name sortKey="Oreh, Adaeze" sort="Oreh, Adaeze" uniqKey="Oreh A" first="Adaeze" last="Oreh">Adaeze Oreh</name><affiliation wicri:level="1"><nlm:affiliation>National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja</wicri:regionArea><wicri:noRegion>Abuja</wicri:noRegion></affiliation></author><author><name sortKey="Patidar, Gopal" sort="Patidar, Gopal" uniqKey="Patidar G" first="Gopal" last="Patidar">Gopal Patidar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Spitalnik, Steven L" sort="Spitalnik, Steven L" uniqKey="Spitalnik S" first="Steven L" last="Spitalnik">Steven L. Spitalnik</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology & Cell Biology, Columbia University, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology & Cell Biology, Columbia University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Vermeulen, Marion" sort="Vermeulen, Marion" uniqKey="Vermeulen M" first="Marion" last="Vermeulen">Marion Vermeulen</name><affiliation wicri:level="1"><nlm:affiliation>The South African National Blood Service, Johannesbur, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The South African National Blood Service, Johannesbur</wicri:regionArea><wicri:noRegion>Johannesbur</wicri:noRegion></affiliation></author><author><name sortKey="Hindawi, Salwa" sort="Hindawi, Salwa" uniqKey="Hindawi S" first="Salwa" last="Hindawi">Salwa Hindawi</name><affiliation wicri:level="1"><nlm:affiliation>Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Berg, Karin" sort="Van Den Berg, Karin" uniqKey="Van Den Berg K" first="Karin" last="Van Den Berg">Karin Van Den Berg</name><affiliation wicri:level="1"><nlm:affiliation>The South African National Blood Service, Johannesbur, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The South African National Blood Service, Johannesbur</wicri:regionArea><wicri:noRegion>Johannesbur</wicri:noRegion></affiliation></author><author><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name><affiliation wicri:level="3"><nlm:affiliation>Etablissement Français du Sang, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vrielink, Hans" sort="Vrielink, Hans" uniqKey="Vrielink H" first="Hans" last="Vrielink">Hans Vrielink</name><affiliation wicri:level="1"><nlm:affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author><author><name sortKey="Young, Pampee" sort="Young, Pampee" uniqKey="Young P" first="Pampee" last="Young">Pampee Young</name><affiliation wicri:level="1"><nlm:affiliation>American Red Cross, Washington, D.C, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>American Red Cross, Washington, D.C</wicri:regionArea><wicri:noRegion>D.C</wicri:noRegion></affiliation></author><author><name sortKey="Devine, Dana" sort="Devine, Dana" uniqKey="Devine D" first="Dana" last="Devine">Dana Devine</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Blood Services, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Blood Services, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="So Osman, Cynthia" sort="So Osman, Cynthia" uniqKey="So Osman C" first="Cynthia" last="So-Osman">Cynthia So-Osman</name><affiliation wicri:level="1"><nlm:affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Erasmus Medical Center, Rotterdam, NL, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Haematology, Erasmus Medical Center, Rotterdam, NL</wicri:regionArea><wicri:noRegion>NL</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vox sanguinis</title><idno type="eISSN">1423-0410</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND OBJECTIVES</b></p><p>COVID-19 convalescent plasma (CCP) has been used, predominantly in high-income countries (HICs) to treat COVID-19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low- and middle-income countries (LMICs) for which data are lacking.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and haematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self-identified expertise and interest. Here, the donor and product-related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre-donation qualification and operational considerations could impede wide adoption.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>There has been wide-scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32533868</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0410</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Vox sanguinis</Title><ISOAbbreviation>Vox Sang.</ISOAbbreviation></Journal><ArticleTitle>Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/vox.12970</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">COVID-19 convalescent plasma (CCP) has been used, predominantly in high-income countries (HICs) to treat COVID-19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low- and middle-income countries (LMICs) for which data are lacking.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and haematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self-identified expertise and interest. Here, the donor and product-related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre-donation qualification and operational considerations could impede wide adoption.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There has been wide-scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.</AbstractText><CopyrightInformation>© 2020 International Society of Blood Transfusion.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Evan M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8181-9517</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Ruchika</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9653-9905</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendel</LastName><ForeName>Silvano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Sirio Libanês, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnouf</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0507-9243</Identifier><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Riyami</LastName><ForeName>Arwa Z</ForeName><Initials>AZ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8649-0650</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Ai Leen</ForeName><Initials>AL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7341-6862</Identifier><AffiliationInfo><Affiliation>Blood Services Group, Health Sciences Authority, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8557-1798</Identifier><AffiliationInfo><Affiliation>Transfusion Medicine Dept, Udine University Hospital, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumont</LastName><ForeName>Larry J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, Denver, CO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Denver, CO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Land</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vice President Clinical Services, Vitalant, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Cheuk-Kwong</ForeName><Initials>CK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3939-564X</Identifier><AffiliationInfo><Affiliation>Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's Park Rise, Kowloon, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oreh</LastName><ForeName>Adaeze</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patidar</LastName><ForeName>Gopal</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9681-3898</Identifier><AffiliationInfo><Affiliation>Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitalnik</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pathology & Cell Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeulen</LastName><ForeName>Marion</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4383-4526</Identifier><AffiliationInfo><Affiliation>The South African National Blood Service, Johannesbur, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hindawi</LastName><ForeName>Salwa</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3804-5434</Identifier><AffiliationInfo><Affiliation>Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Berg</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The South African National Blood Service, Johannesbur, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9310-8322</Identifier><AffiliationInfo><Affiliation>Etablissement Français du Sang, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrielink</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Pampee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>American Red Cross, Washington, D.C, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devine</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Canadian Blood Services, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>So-Osman</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4151-2865</Identifier><AffiliationInfo><Affiliation>Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Haematology, Erasmus Medical Center, Rotterdam, NL, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1K23HL151826-01</GrantID><Agency>EMB's effort is supported in part by the National Heart Lung and Blood Institute</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vox Sang</MedlineTA><NlmUniqueID>0413606</NlmUniqueID><ISSNLinking>0042-9007</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 serotherapy</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">blood donors</Keyword><Keyword MajorTopicYN="N">blood transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32533868</ArticleId><ArticleId IdType="doi">10.1111/vox.12970</ArticleId><ArticleId IdType="pmc">PMC7323328</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Bloch EM, Shoham S, Casadevall A, et al.: Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130(6):2757-2765.</Citation></Reference><Reference><Citation>Duan K, Liu B, Li C, et al.: Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci 2020; 117:9490-6</Citation></Reference><Reference><Citation>Shen C, Wang Z, Zhao F, et al.: Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323:1582</Citation></Reference><Reference><Citation>Chen L, Xiong J, Bao L, et al.: Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20:398-400</Citation></Reference><Reference><Citation>Cheng Y, Wong R, Soo YO, et al.: Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-6</Citation></Reference><Reference><Citation>Casadevall A, Pirofski LA: The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130:1545-1548</Citation></Reference><Reference><Citation>Stokes J Jr, Wolman IJ, Carpenter H, et al.: Prophylactic use of parents' whole blood in anterior poliomyelitis: Philadelphia epidemic of 1932. Am J Dis Child 1935; 50:581-95</Citation></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, et al.: Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609</Citation></Reference><Reference><Citation>Hung IF, To KK, Lee CK, et al.: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56</Citation></Reference><Reference><Citation>Valk SJ, Piechotta V, Chai KL, et al.: Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5(5):Cd013600</Citation></Reference><Reference><Citation>Liu STH, Lin H-M, Baine I, et al.: Convalescent plasma treatment of severe COVID- 19: A matched control study. medRxiv 2020: 2020.05.20.20102236</Citation></Reference><Reference><Citation>Li L, Zhang W, Hu Y, et al.: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020. https://doi.org/10.1001/jama.2020.10044</Citation></Reference><Reference><Citation>Zeng QL, Yu ZJ, Gou JJ, et al.: Effect of Convalescent plasma therapy on viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis 2020; 222(1):38-43.</Citation></Reference><Reference><Citation>Joyner M, Wright RS, Fairweather D, et al.: Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv 2020: 2020.05.12.20099879.</Citation></Reference><Reference><Citation>Smid W, Burnouf T, Epstein J, et al.:Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low- and middle- income countries. Organizing Committee of the ISBT Working Party on Global Blood Safety, 2020. https://isbtweb.org/fileadmin/user_upload/FINAL_Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_in_LMIC.pdf (Last accessed May 17 2020).</Citation></Reference><Reference><Citation>FDA: Recommendations for investigational COVID-19 convalescent plasma. 2020. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (Last accessed May 18 2020).</Citation></Reference><Reference><Citation>An EU programme of COVID-19 convalescent plasma collection and transfusion: guidance on collection, testing, processing, storage, distribution and monitored use. Brussels, 2020. https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf (Last accessed June 5 2020).</Citation></Reference><Reference><Citation>Epstein J, Burnouf T: Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang n/a. https://doi.org/10.1111/vox.12939.</Citation></Reference><Reference><Citation>Chang L, Zhao L, Gong H, et al.: Severe acute respiratory syndrome Coronavirus 2 RNA detected in blood donations. Emerg Infect Dis 2020; 26:1631-1633</Citation></Reference><Reference><Citation>Wang W, Xu Y, Gao R, et al.: Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323(18):1843-1844.</Citation></Reference><Reference><Citation>FDA: Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic (Last accessed June 6 2020).</Citation></Reference><Reference><Citation>JHU: Coronavirus COVID-19 global cases by the center for systems science and engineering at Johns Hopkins. The Center for Systems Science and Engineering (CSSE) at JHU, May 23, 2020 2020. https://coronavirus.jhu.edu/map.html (Last accessed May 23 2020).</Citation></Reference><Reference><Citation>Mapako T, Mvere DA, Chitiyo ME, et al.: Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. Transfusion 2013; 53:2413-21</Citation></Reference><Reference><Citation>Dodd RY, Notari EP, Nelson D, et al.: Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. Transfusion 2016; 56:2781-9</Citation></Reference><Reference><Citation>Chang L, Zhao J, Guo F, et al.: Demographic characteristics of transfusion-transmitted infections among blood donors in China. BMC Infect Dis 2019; 19:514</Citation></Reference><Reference><Citation>Bloch EM, Kipiani E, Shadaker S, et al.: Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. Transfusion 2020; n/a.60(6), 1243-1252.</Citation></Reference><Reference><Citation>Heyns Adu P, Benjamin RJ, Swanevelder JP, et al.: Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA 2006; 295:519-26</Citation></Reference><Reference><Citation>Bloch EM, Vermeulen M, Murphy E: Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev 2012; 26:164-80</Citation></Reference><Reference><Citation>Diakité M, Diawara SI, Tchogang NT, et al.: Knowledge and attitudes of medical personnel in blood transfusion in Bamako, Mali. Transfus Clin Biol 2012; 19:74-7</Citation></Reference><Reference><Citation>Roberts N, James S, Delaney M, et al.: The global need and availability of blood products: a modelling study. Lancet Haematol 2019; 6:e606-e15</Citation></Reference><Reference><Citation>Bednall TC, Bove LL: Donating blood: A meta-analytic review of self-reported motivators and deterrents. Transfus Med Rev 2011; 25:317-334</Citation></Reference><Reference><Citation>Muthivhi TN, Olmsted MG, Park H, et al.: Motivators and deterrents to blood donation among Black South Africans: a qualitative analysis of focus group data. Transfus Med 2015; 25:249-58</Citation></Reference><Reference><Citation>Kouao MD, Dembele B, N'Goran LK, et al.: Reasons for blood donation deferral in sub-Saharan Africa: experience in Ivory Coast. Transfusion 2012; 52:1602-6</Citation></Reference><Reference><Citation>Custer B, Zou S, Glynn SA, et al.: Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop. Transfusion 2018; 58:1307-17</Citation></Reference><Reference><Citation>Busch MP, Bloch EM, Kleinman S: Prevention of transfusion-transmitted infections. Blood 2019; 133:1854-64</Citation></Reference><Reference><Citation>Odekunle FF, Odekunle RO, Shankar S: Why sub-Saharan Africa lags in electronic health record adoption and possible strategies to increase its adoption in this region. Int J Health Sci (Qassim) 2017; 11:59-64</Citation></Reference><Reference><Citation>Accorsi P, Berti P, de Angelis V, et al.: Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus Apher Sci 2020; 102817</Citation></Reference><Reference><Citation>Mathew D, Giles J, Baxter A, et al.:Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. bioRxiv, 2020.</Citation></Reference><Reference><Citation>Wen W, Su W, Tang H, et al.: Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discovery 2020; 6:31</Citation></Reference><Reference><Citation>Robbiani DF, Gaebler C, Muecksch F, et al.: Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv 2020: 2020.05.13.092619.</Citation></Reference><Reference><Citation>Case JB, Rothlauf PW, Chen RE, et al.: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. bioRxiv 2020: 2020.05.18.102038.</Citation></Reference><Reference><Citation>Amanat F, Nguyen T, Chromikova V, et al.: A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv 2020: 2020.03.17.20037713.</Citation></Reference><Reference><Citation>Perera RA, Mok CK, Tsang OT, et al.: Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance 2020; 25:2000421</Citation></Reference><Reference><Citation>Nma OKBA, Muller MA, Li W, et al.: SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv 2020: 2020.03.18.20038059.</Citation></Reference><Reference><Citation>Wu F, Wang A, Liu M, et al.: Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020: 2020.03.30.20047365</Citation></Reference><Reference><Citation>Garcia Godoy LR, Jones AE, Anderson TN, et al.: Facial protection for healthcare workers during pandemics: a scoping review. BMJ Glob Health 2020; 5:e002553.</Citation></Reference><Reference><Citation>Verbeek JH, Ijaz S, Mischke C, et al.: Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database Syst Rev 2016; 4:Cd011621</Citation></Reference><Reference><Citation>Burnouf T, Emmanuel J, Mbanya D, et al.: Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 2014; 384:1347-8</Citation></Reference><Reference><Citation>Buzza M, Marks DC, Capper H, et al.: A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis. Transfusion 2012; 52:1806-13</Citation></Reference><Reference><Citation>Pruett CR, Vermeulen M, Zacharias P, et al.: The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. Transfus Med Rev 2015; 29:35-44</Citation></Reference><Reference><Citation>Weimer A, Tagny CT, Tapko JB, et al.: Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century. Transfusion 2019; 59:412-27</Citation></Reference><Reference><Citation>Burnouf T: Modern plasma fractionation. Transfus Med Rev 2007; 21:101-17</Citation></Reference><Reference><Citation>Hewitt PE, Ijaz S, Brailsford SR, et al.: Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384:1766-73</Citation></Reference><Reference><Citation>O'Riordan J, Boland F, Williams P, et al.: Hepatitis E virus infection in the Irish blood donor population. Transfusion 2016; 56:2868-76</Citation></Reference><Reference><Citation>Matsubayashi K, Nagaoka Y, Sakata H, et al.: Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 2004; 44:934-40</Citation></Reference><Reference><Citation>Gowland P, Fontana S, Niederhauser C, et al.: Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion 2004; 44:1555-61</Citation></Reference><Reference><Citation>Cohen BJ, Beard S, Knowles WA, et al.: Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997; 37:947-52</Citation></Reference><Reference><Citation>Middelburg RA, Porcelijn L, Lardy N, et al.: Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang 2011; 100:327-35</Citation></Reference><Reference><Citation>Ragan I, Hartson L, Pidcoke H, et al.: Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. bioRxiv 2020: 2020.05.03.074971.</Citation></Reference><Reference><Citation>Hashem AM, Hassan AM, Tolah AM, et al.: Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med 2019; 29:434-41</Citation></Reference><Reference><Citation>Pinna D, Sampson-Johannes A, Clementi M, et al.: Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005; 15:269-76</Citation></Reference><Reference><Citation>Ware AD, Jacquot C, Tobian AAR, et al.: Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings. Vox Sang 2018; 113:3-12</Citation></Reference><Reference><Citation>Epstein J, Smid M, Wendel S, et al.: Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. Vox Sang 2020. https://doi.org/10.1111/vox.12964</Citation></Reference><Reference><Citation>Burnouf T: Blood products: unmet needs for essential medicines. Lancet Haematol 2019; 6:e598-e9</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li><li>Arabie saoudite</li><li>Brésil</li><li>Canada</li><li>France</li><li>Inde</li><li>Italie</li><li>Nigeria</li><li>Pays-Bas</li><li>République populaire de Chine</li><li>Singapour</li><li>Taïwan</li><li>États-Unis</li></country><region><li>Arizona</li><li>Colorado</li><li>Illinois</li><li>Maryland</li><li>New Hampshire</li><li>Texas</li><li>État de New York</li><li>État de São Paulo</li><li>Île-de-France</li></region><settlement><li>New York</li><li>Paris</li><li>São Paulo</li></settlement><orgName><li>Université Columbia</li></orgName></list><tree><noCountry><name sortKey="Al Riyami, Arwa Z" sort="Al Riyami, Arwa Z" uniqKey="Al Riyami A" first="Arwa Z" last="Al-Riyami">Arwa Z. Al-Riyami</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Bloch, Evan M" sort="Bloch, Evan M" uniqKey="Bloch E" first="Evan M" last="Bloch">Evan M. Bloch</name></region><name sortKey="Dumont, Larry J" sort="Dumont, Larry J" uniqKey="Dumont L" first="Larry J" last="Dumont">Larry J. Dumont</name><name sortKey="Dumont, Larry J" sort="Dumont, Larry J" uniqKey="Dumont L" first="Larry J" last="Dumont">Larry J. Dumont</name><name sortKey="Dumont, Larry J" sort="Dumont, Larry J" uniqKey="Dumont L" first="Larry J" last="Dumont">Larry J. Dumont</name><name sortKey="Goel, Ruchika" sort="Goel, Ruchika" uniqKey="Goel R" first="Ruchika" last="Goel">Ruchika Goel</name><name sortKey="Goel, Ruchika" sort="Goel, Ruchika" uniqKey="Goel R" first="Ruchika" last="Goel">Ruchika Goel</name><name sortKey="Land, Kevin" sort="Land, Kevin" uniqKey="Land K" first="Kevin" last="Land">Kevin Land</name><name sortKey="Land, Kevin" sort="Land, Kevin" uniqKey="Land K" first="Kevin" last="Land">Kevin Land</name><name sortKey="Spitalnik, Steven L" sort="Spitalnik, Steven L" uniqKey="Spitalnik S" first="Steven L" last="Spitalnik">Steven L. Spitalnik</name><name sortKey="Young, Pampee" sort="Young, Pampee" uniqKey="Young P" first="Pampee" last="Young">Pampee Young</name></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Wendel, Silvano" sort="Wendel, Silvano" uniqKey="Wendel S" first="Silvano" last="Wendel">Silvano Wendel</name></region></country><country name="Taïwan"><noRegion><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name></noRegion><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name></country><country name="Singapour"><noRegion><name sortKey="Ang, Ai Leen" sort="Ang, Ai Leen" uniqKey="Ang A" first="Ai Leen" last="Ang">Ai Leen Ang</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Deangelis, Vincenzo" sort="Deangelis, Vincenzo" uniqKey="Deangelis V" first="Vincenzo" last="Deangelis">Vincenzo Deangelis</name></noRegion></country><country name="République populaire de Chine"><noRegion><name sortKey="Lee, Cheuk Kwong" sort="Lee, Cheuk Kwong" uniqKey="Lee C" first="Cheuk-Kwong" last="Lee">Cheuk-Kwong Lee</name></noRegion><name sortKey="Lee, Cheuk Kwong" sort="Lee, Cheuk Kwong" uniqKey="Lee C" first="Cheuk-Kwong" last="Lee">Cheuk-Kwong Lee</name></country><country name="Nigeria"><noRegion><name sortKey="Oreh, Adaeze" sort="Oreh, Adaeze" uniqKey="Oreh A" first="Adaeze" last="Oreh">Adaeze Oreh</name></noRegion></country><country name="Inde"><noRegion><name sortKey="Patidar, Gopal" sort="Patidar, Gopal" uniqKey="Patidar G" first="Gopal" last="Patidar">Gopal Patidar</name></noRegion></country><country name="Afrique du Sud"><noRegion><name sortKey="Vermeulen, Marion" sort="Vermeulen, Marion" uniqKey="Vermeulen M" first="Marion" last="Vermeulen">Marion Vermeulen</name></noRegion><name sortKey="Van Den Berg, Karin" sort="Van Den Berg, Karin" uniqKey="Van Den Berg K" first="Karin" last="Van Den Berg">Karin Van Den Berg</name></country><country name="Arabie saoudite"><noRegion><name sortKey="Hindawi, Salwa" sort="Hindawi, Salwa" uniqKey="Hindawi S" first="Salwa" last="Hindawi">Salwa Hindawi</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name></region></country><country name="Pays-Bas"><noRegion><name sortKey="Vrielink, Hans" sort="Vrielink, Hans" uniqKey="Vrielink H" first="Hans" last="Vrielink">Hans Vrielink</name></noRegion><name sortKey="So Osman, Cynthia" sort="So Osman, Cynthia" uniqKey="So Osman C" first="Cynthia" last="So-Osman">Cynthia So-Osman</name><name sortKey="So Osman, Cynthia" sort="So Osman, Cynthia" uniqKey="So Osman C" first="Cynthia" last="So-Osman">Cynthia So-Osman</name></country><country name="Canada"><noRegion><name sortKey="Devine, Dana" sort="Devine, Dana" uniqKey="Devine D" first="Dana" last="Devine">Dana Devine</name></noRegion><name sortKey="Devine, Dana" sort="Devine, Dana" uniqKey="Devine D" first="Dana" last="Devine">Dana Devine</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32533868
|texte= Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32533868" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |